Renfro Lindsay A, Sargent Daniel J
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.
Chin Clin Oncol. 2016 Dec;5(6):80. doi: 10.21037/cco.2016.12.02.
The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that could best be answered by pooling individual patient data across many randomized clinical trials. Today, the ACCENT database contains detailed information collected from over 40,000 patients enrolled onto 27 major adjuvant colon cancer trials conducted between 1977 and 2009. Since its inception, the ACCENT group has led many sophisticated analyses addressing a variety of clinical questions, such as the long-term survivorship of colon cancer patients by treatment, the time course of oxaliplatin benefit, and support for the use of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS), among many others. Here, we provide an updated overview of recent important results and future directions of the ACCENT collaboration.
辅助性结肠癌终点（ACCENT）协作组于15年前成立，旨在解决早期结肠癌中的科学问题，而这些问题通过汇总多个随机临床试验中的个体患者数据能够得到最佳解答。如今，ACCENT数据库包含了从1977年至2009年间开展的27项主要辅助性结肠癌试验中入组的40000多名患者收集的详细信息。自成立以来，ACCENT组主导了许多复杂分析，以解决各种临床问题，比如不同治疗方式下结肠癌患者的长期生存率、奥沙利铂获益的时间进程，以及支持将无病生存期（DFS）作为总生存期（OS）的替代终点等诸多问题。在此，我们提供ACCENT协作组近期重要结果及未来方向的最新概述。
